dc.creatorSuenaga, Eunice Mayumi [UNIFESP]
dc.creatorVal, Ligia de Cassia
dc.creatorTominaga, Mineko
dc.creatorSouza Filho, Jose Homero
dc.creatorSoares, Gidel
dc.creatorVioto, Monalisa
dc.creatorNakaie, Clovis Ryuichi [UNIFESP]
dc.date.accessioned2020-07-17T14:02:44Z
dc.date.accessioned2022-10-07T21:03:06Z
dc.date.available2020-07-17T14:02:44Z
dc.date.available2022-10-07T21:03:06Z
dc.date.created2020-07-17T14:02:44Z
dc.date.issued2017
dc.identifierBiomedical Chromatography. Hoboken, v. 31, n. 3, p. -, 2017.
dc.identifier0269-3879
dc.identifierhttps://repositorio.unifesp.br/handle/11600/54983
dc.identifier10.1002/bmc.3823
dc.identifierWOS:000398912500014
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/4026418
dc.description.abstractWe have developed and validated a fast and sensitive ultra high-performance liquid chromatography with positive ion electrospray ionization tandem mass spectrometry method for determining N-butylscopolamine levels in human plasma using propranolol as an internal standard.The acquisition was set up in the multiple reaction monitoring mode with the transitions m/ z 360.3.138.0 for N-butylscopolamine and m/ z 260.2.116.1 for IS.This method uses a liquid-liquid extraction process with dichloromethane.The analyte and IS were chromatographed on a C18, 50x2.1 mm, 1.7 mu m column through isocratic elution with acetonitrile- 5mM ammonium acetate (adjusted to pH 3.0 with formic acid).The method was linear in the 1-1000 pg/ mL range for N-butylscopolamine and was selective, precise, accurate and robust.The validated method was successfully applied to perform a bioequivalence study of the reference (Buscopan r, from Boehringer Ingelheim) and the test sample coated-tablet formulations (from Foundation for Popular Remedy), both containing 10 mg of N-butylscopolamine bromide administered as a single dose.Using 58 healthy volunteers and accounting for the high intra-individual variability confirmed by statistical calculations (38%), the two formulations were considered bioequivalent because the rate and extent of absorption (within 80-125% interval), satisfying international requirements.
dc.languageeng
dc.publisherWiley
dc.relationBiomedical Chromatography
dc.rightsAcesso restrito
dc.subjectbioequivalence
dc.subjecthuman plasma
dc.subjectN-butylscopolamine
dc.subjectpharmacokinetic study
dc.subjectUHPLC-MS/ MS
dc.titleA fast and sensitive UHPLC-MS/ MS method for the determination of N-butylscopolamine in human plasma: application in a bioequivalence study
dc.typeArtigo


Este ítem pertenece a la siguiente institución